By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy & Shipra Gandhi Roswell Park Comprehensive Cancer Center The approved
More
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr. Malak Alharbi of Roswell Park Comprehensive Cancer Center CDK4/6i plus endocrine
More
By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment
More
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for patients with
More
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Attainment of pathological complete response (pCR) of breast cancer is associated with improved long-term outcomes (event-free survival and overall survival) compared to
More
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
More
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
More